MedTrace Logo

The Re-Prosper HF Study

NCT04551222 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 99

Last updated 2026-01-07

No results posted yet for this study

Summary

Heart failure with reduced ejection fraction (HFrEF) is a common cause for admission within the Veterans Affairs (VA) Health Care System.

It is associated with severe impairment of physical and mental health status and carries a high risk of mortality. Even though significant progress has been made in understanding the disease process, currently, its management and treatment is limited.

The investigators have discovered that a commonly used drug for the treatment of gout can be repurposed for the treatment of HFrEF.

The objective of this study is the treatment of outpatient Veterans with HFrEF with probenecid to improve heart and health function. Specifically, the investigators are testing whether oral probenecid administered orally twice per day for 180 days improves heart function as measured via ultrasound of the heart (aim 1); improves exercise capacity (aim 2); and improves self-report heart failure specific health status as measured via questionnaires (aim 3).

Conditions

Interventions

DRUG

probenecid

1 gr. orally of probenecid twice daily for 180 days

DRUG

Placebo

identical tablets to probenecid

Sponsors & Collaborators

  • VA Office of Research and Development

    lead FED

Principal Investigators

  • Jack Rubinstein, MD · Cincinnati VA Medical Center, Cincinnati, OH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-09
Primary Completion
2025-12-31
Completion
2025-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04551222 on ClinicalTrials.gov